These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 28535786)

  • 21. Brain Oxygen Extraction Is Differentially Altered by Alzheimer's and Vascular Diseases.
    Jiang D; Lin Z; Liu P; Sur S; Xu C; Hazel K; Pottanat G; Darrow J; Pillai JJ; Yasar S; Rosenberg P; Moghekar A; Albert M; Lu H
    J Magn Reson Imaging; 2020 Dec; 52(6):1829-1837. PubMed ID: 32567195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular dysfunction-The disregarded partner of Alzheimer's disease.
    Sweeney MD; Montagne A; Sagare AP; Nation DA; Schneider LS; Chui HC; Harrington MG; Pa J; Law M; Wang DJJ; Jacobs RE; Doubal FN; Ramirez J; Black SE; Nedergaard M; Benveniste H; Dichgans M; Iadecola C; Love S; Bath PM; Markus HS; Al-Shahi Salman R; Allan SM; Quinn TJ; Kalaria RN; Werring DJ; Carare RO; Touyz RM; Williams SCR; Moskowitz MA; Katusic ZS; Lutz SE; Lazarov O; Minshall RD; Rehman J; Davis TP; Wellington CL; González HM; Yuan C; Lockhart SN; Hughes TM; Chen CLH; Sachdev P; O'Brien JT; Skoog I; Pantoni L; Gustafson DR; Biessels GJ; Wallin A; Smith EE; Mok V; Wong A; Passmore P; Barkof F; Muller M; Breteler MMB; Román GC; Hamel E; Seshadri S; Gottesman RF; van Buchem MA; Arvanitakis Z; Schneider JA; Drewes LR; Hachinski V; Finch CE; Toga AW; Wardlaw JM; Zlokovic BV
    Alzheimers Dement; 2019 Jan; 15(1):158-167. PubMed ID: 30642436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Use of cerebrospinal fluid (CSF) biomarkers for Alzheimer's type dementia: diagnosis in mild cognitive impairment].
    Verhey FR; Visser PJ
    Ned Tijdschr Geneeskd; 2013; 157(11):A5596. PubMed ID: 23484512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia.
    Stefani A; Sancesario G; Pierantozzi M; Leone G; Galati S; Hainsworth AH; Diomedi M
    J Neurol Sci; 2009 Aug; 283(1-2):109-15. PubMed ID: 19278690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers of Alzheimer's disease and mild cognitive impairment: a current perspective.
    Lewczuk P; Mroczko B; Fagan A; Kornhuber J
    Adv Med Sci; 2015 Mar; 60(1):76-82. PubMed ID: 25579841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
    Di Domenico F; Pupo G; Giraldo E; Badìa MC; Monllor P; Lloret A; Schininà ME; Giorgi A; Cini C; Tramutola A; Butterfield DA; Viña J; Perluigi M
    Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Binswanger's disease: biomarkers in the inflammatory form of vascular cognitive impairment and dementia.
    Rosenberg GA
    J Neurochem; 2018 Mar; 144(5):634-643. PubMed ID: 28902409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Cedarbaum J; Green RC; Harvey D; Jack CR; Jagust W; Luthman J; Morris JC; Petersen RC; Saykin AJ; Shaw L; Shen L; Schwarz A; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2015 Jun; 11(6):e1-120. PubMed ID: 26073027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
    Olsson B; Lautner R; Andreasson U; Öhrfelt A; Portelius E; Bjerke M; Hölttä M; Rosén C; Olsson C; Strobel G; Wu E; Dakin K; Petzold M; Blennow K; Zetterberg H
    Lancet Neurol; 2016 Jun; 15(7):673-684. PubMed ID: 27068280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholinergic circuitry functioning in patients with vascular cognitive impairment--no dementia.
    Bella R; Cantone M; Lanza G; Ferri R; Vinciguerra L; Puglisi V; Pennisi M; Ricceri R; Di Lazzaro V; Pennisi G
    Brain Stimul; 2016; 9(2):225-33. PubMed ID: 26515786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing.
    Blennow K; Vanmechelen E
    J Neural Transm Suppl; 1998; 53():223-35. PubMed ID: 9700660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuropsychological assessment and cerebral vascular disease: the new standards.
    Godefroy O; ; Leclercq C; Bugnicourt JM; Roussel M; Moroni C; Quaglino V; Beaunieux H; Taillia H; Nédélec-Ciceri C; Bonnin C; Thomas-Anterion C; Varvat J; Aboulafia-Brakha T; Assal F
    Rev Neurol (Paris); 2013 Oct; 169(10):779-85. PubMed ID: 23999023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.
    Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L
    Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia.
    Oikonomidi A; Tautvydaitė D; Gholamrezaee MM; Henry H; Bacher M; Popp J
    J Alzheimers Dis; 2017; 60(1):273-281. PubMed ID: 28826184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting.
    Malnar M; Kosicek M; Bene R; Tarnik IP; Pavelin S; Babic I; Brajenovic-Milic B; Hecimovic H; Titlic M; Trkanjec Z; Demarin I; Hecimovic S
    Acta Neurobiol Exp (Wars); 2012; 72(3):264-71. PubMed ID: 23093013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
    Mattsson N; Lönneborg A; Boccardi M; Blennow K; Hansson O;
    Neurobiol Aging; 2017 Apr; 52():196-213. PubMed ID: 28317649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.